Products
Anifrolumab Biosimilar Monoclonal Antibody (IFNAR1) for Research
Pre-Made Anifrolumab biosimilar, Whole mAb, Anti-IFNAR1 Antibody: Anti-AVP/IFN-alpha-REC/IFNAR/IFNBR/IFRC therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Anifrolumab[1] is a monoclonal antibody designed for the treatment of systemic lupus erythematosus (SLE). It binds to the type I interferon receptor, blocking the activity of type I interferons such as interferon-α and interferon-β.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-026-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Anifrolumab biosimilar, Whole mAb, Anti-IFNAR1 Antibody: Anti-AVP/IFN-alpha-REC/IFNAR/IFNBR/IFRC therapeutic antibody |
| INN Name | Anifrolumab |
| Target | IFNAR1 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | 4qxg:HL |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2013 |
| Year Recommended | 2014 |
| Companies | Medarex;Medical University of Vienna;MedImmune |
| Conditions Approved | Systemic lupus erythematosus |
| Conditions Active | Lupus nephritis |
| Conditions Discontinued | Scleroderma |
| Development Tech | Medarex UltiMAb Mouse |
About target - IFNAR1
1. Protein Interferon alpha/beta receptor 1
2. Gene IFNAR1
3. Organism Homo sapiens (Human)
Function
Component of the receptor for type I interferons, including interferons alpha, IFNB1 and IFNW1 (PubMed:2153461, PubMed:7665574, PubMed:10049744, PubMed:14532120, PubMed:15337770, PubMed:21854986).
Functions in general as heterodimer with IFNAR2 (PubMed:7665574, PubMed:10049744, PubMed:21854986).
Type I interferon binding activates the JAK-STAT signaling cascade, and triggers tyrosine phosphorylation of a number of proteins including JAKs, TYK2, STAT proteins and the IFNR alpha- and beta-subunits themselves (PubMed:7665574, PubMed:21854986, PubMed:32972995).
Can form an active IFNB1 receptor by itself and activate a signaling cascade that does not involve activation of the JAK-STAT pathway (By similarity).
